Alzheimer's Disease Drug Landscape 2026

Disease-modifying therapies, symptomatic treatments, and clinical trial intelligence

Data updated: Mar 29, 2026

Approved Drugs

260

Pipeline Trials

260

Active Trials

184

Companies

6.9M US patients

Patient Population

Market: $13B (2025)

✦

New in 2025-2026

LEQEMBI IQLIK (2025)

Overview

Alzheimer's disease is the most common cause of dementia, affecting nearly 7 million Americans and projected to reach 13 million by 2050. The treatment landscape has undergone a revolutionary transformation with the approval of disease-modifying anti-amyloid antibodies (lecanemab, donanemab) that can slow cognitive decline. Traditional symptomatic treatments (cholinesterase inhibitors, memantine) remain widely used but do not alter disease progression. The pipeline is extraordinarily active with novel mechanisms including anti-tau antibodies, neuroinflammation modulators, synaptic protection agents, and GLP-1 agonists being repurposed for neuroprotection. Major investments from Eli Lilly, Biogen, Eisai, Roche, and numerous biotechs make Alzheimer's one of the most competitive therapeutic areas.

Historical Context

First described in 1906 by German psychiatrist Alois Alzheimer, who examined a 51-year-old woman named Auguste Deter with progressive memory loss, confusion, and behavioral changes. Upon her death in 1906, Alzheimer performed an autopsy and identified the hallmark plaques and tangles in her brain tissue using a silver staining technique. His colleague Emil Kraepelin coined the term 'Alzheimer's disease' in 1910. For decades it was considered a rare presenile dementia until the 1970s when researchers recognized it was the same pathology seen in elderly dementia patients.

1906

Alois Alzheimer

University of Munich, Germany

Originally: "Presenile Dementia"

🔒

Pro Intelligence — Coming Soon

Deeper insights for pharma professionals, investors, and analysts.

● Treatment Evolution Timeline — Mechanism shifts over 25 years

● Full Drug Dataset — FDA links, trial data, biosimilars

● Full Pipeline Dataset — All trials with NCT IDs

● Efficacy Comparison — Remission rates from FDA labels

● PDUFA Calendar — Upcoming FDA decision dates

● Company Analysis — Originators, biosimilars, pipeline by phase

● Head-to-Head Trials — Direct comparisons

Join the waitlist below to get notified when Pro launches.

Mechanism Landscape

Current Crohn's disease treatments target several key inflammatory pathways. TNF inhibitors like Remicade and Humira remain widely used, while newer IL-23 blockers and JAK inhibitors offer alternatives for patients who don't respond to anti-TNF therapy.

Amyloid beta

LEQEMBI IQLIK, KISUNLA

Acetylcholinesterase

ZUNVEYL, MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

Unknown

REXULTI, NEURACEQ

Cholinesterase

RIVASTIGMINE TARTRATE, EXELON

MAO-A

TAUVID

Amyloid beta plaques

AMYVID

Note: Counts include originator drugs only. Biosimilars are tracked separately.

FDA-Approved Drugs Free

14 approved

FDA-approved biologics and small molecules for Crohn's disease, including TNF inhibitors, IL-23 blockers, integrin antagonists, and JAK inhibitors.

Drug	Company	Mechanism	Approved
LEQEMBI IQLIK LECANEMAB-IRMB	EISAI INC	Amyloid beta	2025
ZUNVEYL BENZGALANTAMINE GLUCONATE	ALPHA COGNITION	Acetylcholinesterase	2024
KISUNLA DONANEMAB-AZBT	Eli Lilly	Amyloid beta	2024
LEQEMBI LECANEMAB-IRMB	EISAI INC	Amyloid beta	2023
TAUVID FLORTAUCIPIR F-18	AVID RADIOPHARMS INC	MAO-A	2020
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE DONEPEZIL HYDROCHLORIDE	MACLEODS PHARMS LTD	Acetylcholinesterase	2017
REXULTI BREXPIPRAZOLE	OTSUKA	Unknown	2015
NEURACEQ FLORBETABEN F-18	LIFE MOLECULAR	Unknown	2014
NAMZARIC DONEPEZIL HYDROCHLORIDE	AbbVie	Acetylcholinesterase	2014
VIZAMYL FLUTEMETAMOL F-18	GE HEALTHCARE	Amyloid beta	2013
AMYVID FLORBETAPIR F-18	AVID RADIOPHARMS INC	Amyloid beta plaques	2012
RIVASTIGMINE TARTRATE RIVASTIGMINE TARTRATE	ALEMBIC PHARMS LTD	Cholinesterase	2007
EXELON RIVASTIGMINE	Novartis	Cholinesterase	2000
ARICEPT DONEPEZIL HYDROCHLORIDE	EISAI INC	Acetylcholinesterase	1996

Pipeline Snapshot Free

Active clinical trials for Crohn's disease drugs across all development phases. Includes novel mechanisms like TL1A inhibitors, next-generation IL-23 blockers, and S1P modulators currently in Phase 2 and Phase 3 studies.

Phase 3 Trials

39 recruiting

122

Phase 2 Trials

62 recruiting

Phase 1 Trials

33 recruiting

Full pipeline dataset coming soon in Pro

Key Companies Free

Major pharmaceutical companies active in Crohn's disease drug development.

Bristol-Myers Squibb Eli Lilly Roche Sunnybrook Health Sciences Centre LuyeGroup Imperialllege London EISAI Novartis Eisai Regeneration Biomedical NYU Langone Health Green Valley (Shanghai)

Detailed competitive analysis (originators, biosimilars, pipeline breakdown) available in Pro.

Upcoming Catalysts Free

Event	Drug/Company	Timeline
Phase 3	Trontinemab Hoffmann-La Roche	TBD
Phase 3	buntanetap/posiphen Annovis Bio Inc.	TBD
Phase 3	KarXT Bristol-Myers Squibb	TBD
Phase 3	Lecanemab Eisai Inc.	TBD
Phase 3	KarXT Karuna Therapeutics, Inc., a Bristol Myers Squibb company	TBD

Stay Updated

Get notified when we publish new IBD intelligence and Pro launches.

Subscribe for Updates →

Frequently Asked Questions

What are the FDA-approved drugs for Alzheimer's disease?

FDA-approved treatments include disease-modifying anti-amyloid antibodies lecanemab (Leqembi, 2023) and donanemab (Kisunla, 2024). Symptomatic treatments include cholinesterase inhibitors donepezil (Aricept), rivastigmine (Exelon), galantamine (Razadyne), and the NMDA antagonist memantine (Namenda). Aducanumab (Aduhelm) received accelerated approval in 2021 but was withdrawn in 2024.

What is the Alzheimer's disease drug pipeline?

The Alzheimer's pipeline includes over 140 drugs in clinical development, with anti-tau antibodies, GLP-1 agonists (being repurposed from diabetes), neuroinflammation modulators (TREM2 agonists), and combination approaches being the most active areas. Major Phase 3 programs from Eli Lilly, Roche, Biogen, and Novo Nordisk are advancing.

How do anti-amyloid antibodies work?

Anti-amyloid antibodies like lecanemab and donanemab bind to and help clear amyloid-beta plaques from the brain. Clinical trials have shown they can slow cognitive decline by 25-35% in early Alzheimer's patients, though they require regular IV infusions and carry risks of amyloid-related imaging abnormalities (ARIA).

Which companies are leading Alzheimer's drug development?

Eli Lilly (donanemab, multiple pipeline assets), Biogen/Eisai (lecanemab), Roche (gantenerumab, anti-tau programs), Novo Nordisk (GLP-1 for neurodegeneration), and numerous biotechs including Denali, Alector, and Annovis Bio are leading Alzheimer's R&D.